Atopic Dermatitis (Eczema) clinical trials at UC Irvine
4 in progress, 2 open to eligible people
Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
open to eligible people ages 12-17
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
Irvine, California and other locations
Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
open to all eligible people
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Irvine, California and other locations
Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
Sorry, in progress, not accepting new patients
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Irvine, California and other locations
Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Sorry, in progress, not accepting new patients
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Irvine, California and other locations
Our lead scientists for Atopic Dermatitis (Eczema) research studies include Natasha Mesinkovska, MD.
Last updated: